169 related articles for article (PubMed ID: 9013365)
1. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants.
Jusko WJ; Ferron GM; Mis SM; Kahan BD; Zimmerman JJ
J Clin Pharmacol; 1996 Dec; 36(12):1100-6. PubMed ID: 9013365
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients.
Brattström C; Säwe J; Tydén G; Herlenius G; Claesson K; Zimmerman J; Groth CG
Ther Drug Monit; 1997 Aug; 19(4):397-406. PubMed ID: 9263380
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.
Zimmerman JJ; Kahan BD
J Clin Pharmacol; 1997 May; 37(5):405-15. PubMed ID: 9156373
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Brattström C; Tydén G; Säwe J; Herlenius G; Claesson K; Groth CG
Transplant Proc; 1996 Apr; 28(2):985-6. PubMed ID: 8623489
[No Abstract] [Full Text] [Related]
5. Population pharmacokinetics of sirolimus in kidney transplant patients.
Ferron GM; Mishina EV; Zimmerman JJ; Jusko WJ
Clin Pharmacol Ther; 1997 Apr; 61(4):416-28. PubMed ID: 9129559
[TBL] [Abstract][Full Text] [Related]
6. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
Clin Pharmacol Ther; 1998 Jan; 63(1):48-53. PubMed ID: 9465841
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Johnson EM; Zimmerman J; Duderstadt K; Chambers J; Sorenson AL; Granger DK; Almond PS; Fryer Jp; Leventhal JR; Scarola J; Matas AJ; Canafax DM
Transplant Proc; 1996 Apr; 28(2):987. PubMed ID: 8623490
[No Abstract] [Full Text] [Related]
8. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.
Kovarik JM; Hartmann S; Figueiredo J; Rordorf C; Golor G; Lison A; Budde K; Neumayer HH
Pharmacotherapy; 2002 Feb; 22(2):154-9. PubMed ID: 11837553
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus: a new agent for clinical renal transplantation.
Kahan BD
Transplant Proc; 1997; 29(1-2):48-50. PubMed ID: 9123092
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers.
Chakraborty A; Blum RA; Mis SM; Cutler DL; Jusko WJ
J Clin Pharmacol; 1999 Jun; 39(6):624-35. PubMed ID: 10354967
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
Wang HF; Qiu F; Wu X; Fang J; Crownover P; Korth-Bradley J; Schulman S
Clin Pharmacol Drug Dev; 2014 May; 3(3):235-41. PubMed ID: 27128614
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions between zileuton and prednisone.
Awni WM; Cavanaugh JH; Tzeng TB; Witt G; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():105-11. PubMed ID: 8620666
[TBL] [Abstract][Full Text] [Related]
15. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.
Murgia MG; Jordan S; Kahan BD
Kidney Int; 1996 Jan; 49(1):209-16. PubMed ID: 8770969
[TBL] [Abstract][Full Text] [Related]
16. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.
Kovarik JM; Noe A; Wang Y; Mueller I; DeNucci G; Schmouder RL
Eur J Clin Pharmacol; 2006 May; 62(5):361-6. PubMed ID: 16547714
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
19. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
